Medicine · Français

Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?

deadline 2027-04-30 confidence medium tier 4 evidence
48%PolySignal estimate
⚠ Evidence cap applied: the model proposed 65%, brought back to 48% for lack of sources solid enough to justify the departure from the base rate.

Resolution criterion

Yes if the FDA approves the paediatric sNDA by 30 April 2027 (Drugs@FDA or a Shionogi release). A complete response letter, a postponed PDUFA date, or no decision by that date all count as no. An approval covering only one of the two indications (hospital-acquired pneumonia or complicated urinary tract infections) counts as no for this question; flag for manual review.

Verified starting state

sNDA accepted, PDUFA date 23 February 2027, for hospital-acquired pneumonia and complicated urinary tract infections in children from 26 weeks gestational age, based on three studies totalling 154 children. The paediatric extrapolation rests on a small sample. (17 July 2026)

What pushes it up

What pushes it down

What would move this number most

Whether the FDA issues a complete response letter or postpones the PDUFA date, which would prevent approval by 30 Apr 2027

How this number is built

Deadline2027-04-30
Base rate40%
Best evidencetier 4 · 0 article(s) used
Independent runs48 · 48 (spread 0 pts)
Confidencemedium
Evidence capapplied: 65% brought back to 48%
Last revised2026-09-21 22:26
Modelopenai/gpt-oss-120b (Groq)

Probability history

2026-09-21 22:26 48% 5 article(s) on file · openai/gpt-oss-120b (Groq)

Reasons not recorded for this revision (detailed history has only been kept since recently).

2026-09-19 13:46 80% 5 article(s) on file · gemini-3.5-flash

Reasons not recorded for this revision (detailed history has only been kept since recently).